J Hepatol:发现外泌体协助丙型肝炎病毒免疫逃逸过程中的重要调控因子

2019-03-18 佚名 上海巴斯德研究所

3月15日,国际学术期刊Journal of Hepatology在线发表了中国科学院上海巴斯德研究所龙钢课题组的研究论文“Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes”。

3月15日,国际学术期刊Journal of Hepatology在线发表了中国科学院上海巴斯德研究所龙钢课题组的研究论文“Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes”。

病毒在宿主的长期协同进化中,宿主发展出多种识别病毒的机制,而病毒也反过来利用宿主自身原件和识别机制去帮助其入侵和逃逸免疫体系。近年来大量的研究集中在病毒本身如何引起宿主的防御机制以及相应的构建特定的类病毒颗粒作为疫苗刺激免疫系统产生抗体,然而有些病毒在免疫系统已经做出反应并产生抗体的情况下,正是依靠“劫持”宿主囊泡释放途径制造自身的“替身”(类病毒颗粒)以逃逸抗体的识别和杀灭。因此,利用适当的研究模型,研究可能被病原所利用的宿主囊泡释放途径,对于更好地理解病毒-宿主互作,以及寻找潜在的病毒感染的防控和治疗手段具有重要意义。

在该项研究中,研究人员以丙型肝炎病毒(HCV)为研究模型,发现病毒膜蛋白可以通过外泌体途径释放到细胞外且该过程受到syntenin蛋白的调控。这种膜蛋白-外泌体存在并独立于HCV感染性病毒颗粒,却同样可以被HCV膜蛋白特异性抗体所识别,从而帮助真正的病毒逃逸抗体的中和。进一步的研究发现血清中syntenin含量不同的HCV患者,其体内产生的血清抗体对HCV病毒的中和能力也不同,敲低人原代肝细胞中syntenin的水平后产生的子代病毒逃逸特异性抗体的能力也会降低。该研究结果揭示了syntenin在病毒利用宿主囊泡释放途径帮助自身逃逸抗体中和过程中的调控功能,为研究病毒逃逸宿主免疫系统和外泌体的包装提供了新线索。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1274659, encodeId=964612e465994, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427306, encodeId=6259142e30693, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429557, encodeId=481b142955e1e, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362947, encodeId=717536294eb4, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 18 20:54:24 CST 2019, time=2019-03-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1274659, encodeId=964612e465994, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427306, encodeId=6259142e30693, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429557, encodeId=481b142955e1e, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362947, encodeId=717536294eb4, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 18 20:54:24 CST 2019, time=2019-03-18, status=1, ipAttribution=)]
    2019-03-20 gwc384
  3. [GetPortalCommentsPageByObjectIdResponse(id=1274659, encodeId=964612e465994, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427306, encodeId=6259142e30693, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429557, encodeId=481b142955e1e, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362947, encodeId=717536294eb4, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 18 20:54:24 CST 2019, time=2019-03-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1274659, encodeId=964612e465994, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427306, encodeId=6259142e30693, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429557, encodeId=481b142955e1e, content=<a href='/topic/show?id=534e2090181' target=_blank style='color:#2F92EE;'>#丙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20901, encryptionId=534e2090181, topicName=丙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26a4213133, createdName=anan, createdTime=Wed Mar 20 10:28:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362947, encodeId=717536294eb4, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Mar 18 20:54:24 CST 2019, time=2019-03-18, status=1, ipAttribution=)]
    2019-03-18 一个字-牛

    学习了谢谢分享

    0

相关资讯

歌礼丙肝创新药戈诺卫进入成都医保

歌礼制药有限公司(歌礼制药 1672.HK),一家致力于解决抗病毒、癌症及脂肪肝病三大领域中尚未被满足医疗需求的生物科技公司,今日宣布,根据成都市医疗保险管理局文件通知,戈诺卫®(达诺瑞韦)正式被纳入成都市丙型肝炎门诊医疗费分类付费药品范围。这是继被纳入天津市“基本医疗保险丙型肝炎门诊医疗费用按人头付费试点”药品报销范围及获绍兴市政府财政补助后,戈诺卫®在提高药物可及性方面取得的又一大进展。戈诺卫

J Diabetes:复旦大学附属中山医院于明香教授团队研究:HCV感染使肾移植患者糖尿病风险增加3倍

日前,复旦大学附属中山医院内分泌科于明香教授团队在Diabetes杂志发表的研究结果显示,术前丙型肝炎(HCV)感染的成人在接受肾移植后患糖尿病的风险比乙型肝炎(HBV)感染和无感染的成人增加3倍以上。

知名肝病专家王宇明:丙肝新药应尽快纳入医保

在丙肝新药DAA纳入基药目录后,希望其早日纳入医保体系的呼声越来越高。

丙肝可被治愈,但还有更关键的问题困扰这200万美国人

2018年11月6日星期二(健康日新闻)——超过200万美国人患有丙型肝炎——根据一项新的政府研究,阿片类药物的流行是这个问题的主要原因。

加强高危人群丙肝筛查,提高普通人群防治意识

世界卫生组织(WHO)2016年的数据显示,全球有1.3亿至1.5亿丙肝患者,每年大约有70万人因未得到治疗而死亡。

丙肝援助项目医学中心首次落地北京,低保患者可获免费新药

记者从北京佑安医院获悉,由中国初级卫生保健基金会发起的“‘上下求索,治愈丙肝’——丙肝患者援助项目”落户该院,这是该项目在北京市成立的首个医学合作中心(以下简称“中心”)。通过这个项目,北京市低保丙肝患者可以免费获得最新的丙肝治疗药物。去年以来多个用于治疗丙型肝炎的口服直接抗病毒药物(DAA)的获批上市,使得丙型肝炎的治疗取得突破性进展。与传统的注射长效干扰素疗法相比,DAA具有疗程短、副作用小、